

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Cryofocus Medtech (Shanghai) Co., Ltd.**

**康豐生物科技(上海)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6922)**

## **ANNOUNCEMENT IN RELATION TO COMPLETION OF H SHARE FULL CIRCULATION**

Reference is made to (i) the announcement of Cryofocus Medtech (Shanghai) Co., Ltd. (康豐生物科技(上海)股份有限公司) (the “**Company**”) dated March 11, 2024 in relation to the issuance of the Filing Notice by the CSRC in respect of the CSRC Filing, and (ii) the announcement of the Company dated April 3, 2024 in relation to the grant of listing approval by the Stock Exchange for the implementation of the H share full circulation (collectively, the “**Announcements**”). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

### **COMPLETION OF THE H SHARE FULL CIRCULATION**

The Board is pleased to announce that the conversion of 29,341,981 Unlisted Shares into H Shares was completed on September 5, 2024, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on September 6, 2024. The Participating Shareholders may conduct trading of the Converted H Shares subject to the completion of the applicable onshore arrangement procedures.

## SHAREHOLDING STRUCTURE

Upon completion of the Conversion and Listing, the share capital structure of the Company is as follows:

Description of shares	As at the date of this announcement		Upon completion of the Conversion and Listing	
	<i>Number of shares</i>	<i>Approximate percentage</i>	<i>Number of shares</i>	<i>Approximate percentage</i>
H Shares	114,096,598	47.72%	143,438,579	59.99%
Unlisted Shares	125,013,402	52.28%	95,671,421	40.01%
<b>Total</b>	<b>239,110,000</b>	<b>100.00%</b>	<b>239,110,000</b>	<b>100.00%</b>

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Cryofocus Medtech (Shanghai) Co., Ltd.**  
**Mr. LI Kejian**  
*Chairman of the Board*

Hong Kong, September 5, 2024

*As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.*